Immune Globulin, Intramuscular
- Atc Codes:J06BA01
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Beriglobin P, Gammanorm, Subcuvia, Vibaglobin; Belgium: Subcuvia, Vivaglobin; Bulgaria: Human Normal Immunoglobulin; Cyprus: Subcuvia, Subgam; Czech Republic: Gammanorm, Igamplia, Pasteurised Human Immunoglobulin, Subcuvia, Vivaglobin; Denmark: Beriglobin, Gammanorm, Subcuvia, Vivaglobin; Estonia: Gammanorm, Subcuvia; Finland: Gammanorm, Subcuvia, Vivaglobin; France: Gammanorm, Subcuvia, Vivaglobin; Germany: Beriglobin, Gammanorm, Subcuvia, Vivaglobin; Greece: Subcuvia, Vivaglobin; Hungary: Gammanorm, Subcuvia; Ireland: Rophylac, Subcuvia; Italy: Subcuvia, Vivaglobin; Latvia: Subcuvia; Lithuania: Subcuvia; Netherlands: Gammanorm, GammaQuin; Poland: Bioglobulin, Gammanorm, Subcuvia, Vivaglobin; Portugal: Gammanorm, Subcuvia, Vivaglobin; Romania: Beriglobin; Slovakia: Gammanorm, Igamplia, Vivaglobin; Spain: Beriglobina P, Gammaglobulina Humana Pasteurizada, Vivaglobin; Sweden: Beriglobin, Gammanorm, Subcuvia, Vivaglobin; UK: Subgam, Vivaglobin.
North America
Canada: Gamastan, Immune Serum Globulin (Human), Vivaglobin; USA: Vivaglobin.
Latin America
Argentina: Igg Intramuscular; Brazil: Beriglobina, Imunoglobulin-Imunoglobulina Humana, Venimmuna; Mexico: Beriglobina P.
Drug combinations
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Serums. Immune Globulin. (ATC-Code: J06BA01).
Mechanism of action
Increases antibody titer and antigen-antibody reaction potential.
Therapeutic use
Provides passive immunity in susceptible individuals under the following circumstances: Hepatitis A, measles, varicella, rubella, tetanus, and immunoglobulin deficiency.
Pregnancy and lactiation implications
Immune globulins cross placenta in increased amounts after 30 weeks gestation. Reproduction studies not carried out.
Unlabeled use
Contraindications
Hypersensitivity to immune globulin or any component of the formulation. IgA deficiency. Severe thrombocytopenia or coagulation disorders where I.M. injections are contraindicated.
Warnings and precautions
Hypersensitivity and anaphylactic reactions can occur. Product of human plasma. Not for I.V. administration. Skin testing should be avoided (local irritation can occur).